Table 1 Demographic and clinical characteristics at baseline (fasting state) for males versus females.

From: Gender differences in fasting and postprandial metabolic traits predictive of subclinical atherosclerosis in an asymptomatic Chinese population

Variable

Males (n = 55)

Females (n = 46)

Mean difference (CI)

P value

Gender

 Male

 Female

BMI (kg/m2)

23.77 ± 2.82

23.18 ± 2.91

− 0.59 (− 1.72, 0.55)

0.3081

Weight (kg)

70.45 ± 9.59

59.05 ± 7.74

− 11.39 (− 14.88, − 7.91)

 < .0001

Glucose (mmol/L)

5.11 ± 0.40

4.97 ± 0.36

− 0.14 (− 0.30, 0.0076)

0.0624

Insulin (μU/mL )

8.25 ± 5.61

8.0 ± 4.71

− 0.25(− 2.32, 1.82)

0.8132

c-peptide (ng/mL)

2.01 ± 0.85

1.97 ± 0.76

− 0.041 (− 0.36, 0.28)

0.7994

LDL-C (mmol/L)

3.35 ± 0.74

3.25 ± 0.73

− 0.10 (− 0.39, 0.19)

0.4934

HDL-C (mmol/L)

1.43 ± 0.30

1.67 ± 0.32

0.24 (0.12, 0.36)

0.0002

Triacylglycerol (mmol/L)

1.21 ± 0.67

0.88 ± 0.41

− 0.33 (− 0.55, − 0.12)

0.0028

Cholesterol (mmol/L)

5.33 ± 0.86

5.32 ± 0.88

− 0.014 (− 0.36, 0.33)

0.9343

Age

47.53 ± 4.05

47.85 ± 4.54

− 0.32 (− 1.38, 2.02)

0.7084

Framingham Score

5.56 ± 2.52

5.76 ± 2.97

0.20 (− 0.89, 1.28)

0.7188

HOMA-IR

2.05 ± 1.50

1.89 ± 1.16

− 0.16 (− 0.70, 0.38)

0.5615

HOMA-β

84.36 ± 54.66

93.52 ± 54.17

− 9.16 (− 12.42, 30.74)

0.4018

Adiponectin (pg/mL)

5,029,254 ± 2,137,308

6,058,005 ± 2,196,463

1,028,751 (− 170,674, 1,886,829)

0.0193

TNFα (pg/mL)

20.44 ± 15.73

12.78 ± 7.13

− 7.66 (− 12.64, − 2.67)

0.0018

PAI-1 (pg/mL)

29,484.4 ± 11,363.7

23,313.9 ± 9231.6

− 6170.6 (− 10,312.9, − 2028.2)

0.0039

Leptin (pg/mL)

2446.2 ± 2267.6

8701.9 ± 6189.6

6255.7 (4473.1, 8038.4)

 < .0001

  1. P value from 2-sample t test for continuous variables and Fisher’s exact test for categorical variables. BMI, Body mass index; LDL-C, Cholesterol in low-density lipoprotein; HDL-C, Cholesterol in high-density lipoprotein; HOMA-IR, Homeostasis model assessment of insulin resistance; HOMA-β, Homeostasis model assessment of β-cell function; TNFα, Tumor necrosis factor alpha; PAI-1, Plasminogen activator inhibitor-1. HOMA-IR was calculated by fasting plasma insulin (uU/mL) × fasting plasma glucose (mmol/L)/22.5. HOMA-β was calculated by 20 × fasting plasma insulin (uU/mL)/fasting plasma glucose (mmol/L)–3.5.
  2. Significant values are in bold.
Back to article page